1 February 2017 - The 1 February 2017 issue of the Schedule of Pharmaceutical Benefits sees a number of new & revised listings.

The new & revised listings are:

• Ceritinib (Zykadia)  - new medicine
  
• Ixekizumab (Taltz) - new medicine
  
• Lenalidomide (Revlimid) - new indication
  
• Olaparib (Lynparza) - new medicine
  
• Riociguat (Adempas) - new indication
  
• Tiotropium bromide monohydrate (Spiriva) - new indication
  

Read summary of changes